<! DOCTYPE = html>
<html>
<title>CS657 - Prescription</title>
<style>
div.container {
		width: 100%;
		border: 1px solid gray;
}

header{
		padding: 0.5em;
		#color: black;
		background-color: orange;
		clear: left;
		text-align: center;
}
.footer{
		padding : 1em;
		background-color: orange;
		text-align: center;
		<!--- position: fixed;>
		bottom : 0;
		width : 100%;
}

nav {
		float: left;
		max-width: 160px;
		margin: 0;
		padding: 1em;
}

nav ul {
		list-style-type: none;
		padding: 0;
}
	 
nav ul a {
		text-decoration: none;
}

article {
		margin-left: 170px;
		border-left: 1px solid gray;
		padding: 1em;
		overflow: hidden;
}
table {
		font-family: arial, sans-serif;
		border-collapse: collapse;
		width: 80%;
}

td, th {
		border: 4px solid #000000;
		text-align: middle;
		padding: 8px;
}

tr:nth-child(even) {
		background-color: #eeeeee;
}	

div.box {
		background-color: white;
		width: 300px;
		border: 2px solid green;
		padding: 10px;
		margin: 25px;
}
</style>
<body>
<div class="container">
	<header><h1>
		IIT Kanpur Medical Labs</h1>
	</header>
	<hr>	<h2> Precription for the query: </h2>
	<div class="box">
	back pain, fever, nausea, urinary incontinence, stress, urge
	</div>
	<hr>	<h2>
		Identified Disease: </h2>
	<div class="box">
	Urinary Incontinence, Stress
	</div>
	<hr>	<h2>More Symptoms: </h2>
	<div class="box">
	Headache, Diarrhea, Back Pain, Vocal Cord Paralysis, Encopresis
	</div>
		<hr><h2>
Medication:</h2>
<table>
	<tr>
		<th>Serial No</th>
		<th>Drug Name</th>
		<th>Group</th>
		<th>Indication</th>
	</tr>	<tr>
		<td>1.</td>
		<td>Mirabegron</td>
		<td>Approved</td>
		<td>Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.</td>
	</tr>	<tr>
		<td>2.</td>
		<td>Dicyclomine</td>
		<td>Approved</td>
		<td>For the treatment of functional bowel/irritable bowel syndromeincluding Colicky abdominal pain; diverticulitis</td>
	</tr>	<tr>
		<td>3.</td>
		<td>Solifenacin</td>
		<td>Approved</td>
		<td>For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.</td>
	</tr>	<tr>
		<td>4.</td>
		<td>Fesoterodine</td>
		<td>Approved</td>
		<td>For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).</td>
	</tr>	<tr>
		<td>5.</td>
		<td>Trospium</td>
		<td>Approved</td>
		<td>For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.</td>
	</tr>	<tr>
		<td>6.</td>
		<td>Flavoxate</td>
		<td>Approved</td>
		<td>For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.</td>
	</tr>	<tr>
		<td>7.</td>
		<td>Duloxetine</td>
		<td>Approved</td>
		<td>For the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women.</td>
	</tr>	<tr>
		<td>8.</td>
		<td>Oxybutynin</td>
		<td>Approved, Investigational</td>
		<td>For the treatment of overactive bladder.</td>
	</tr>	<tr>
		<td>9.</td>
		<td>Tolterodine</td>
		<td>Approved, Investigational</td>
		<td>For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).</td>
	</tr>	<tr>
		<td>10.</td>
		<td>Darifenacin</td>
		<td>Approved, Investigational</td>
		<td>For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.</td>
	</tr>	<tr>
		<td>11.</td>
		<td>Propiverine</td>
		<td>Approved, Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>12.</td>
		<td>Solabegron</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in diabetes mellitus type 2, irritable bowel syndrome (IBS), and urinary incontinence.</td>
	</tr>	<tr>
		<td>13.</td>
		<td>Casopitant</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in urinary incontinence and adverse effects (chemotherapy).</td>
	</tr>	<tr>
		<td>14.</td>
		<td>Resiniferatoxin</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in interstitial cystitis and urinary incontinence.</td>
	</tr>	<tr>
		<td>15.</td>
		<td>Elocalcitol</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in benign prostatic hyperplasia, urinary incontinence, prostate disorders, and infertility.</td>
	</tr>	<tr>
		<td>16.</td>
		<td>AP-1034</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in urinary incontinence.</td>
	</tr>	<tr>
		<td>17.</td>
		<td>OPC-51803</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in nocturia (frequent nighttime urination) and urinary incontinence.</td>
	</tr>	<tr>
		<td>18.</td>
		<td>DDP-200</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in urinary incontinence.</td>
	</tr>	<tr>
		<td>19.</td>
		<td>BK-MDA</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>20.</td>
		<td>KW-7158</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in urinary incontinence.</td>
	</tr>	<tr>
		<td>21.</td>
		<td>AZD0947</td>
		<td>Investigational</td>
		<td>Intended for the treatment of urinary incontinence.</td>
	</tr>	<tr>
		<td>22.</td>
		<td>AV608</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in anxiety disorders, irritable bowel syndrome (IBS), and urinary incontinence.</td>
	</tr>	<tr>
		<td>23.</td>
		<td>Enobosarm</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>24.</td>
		<td>R450</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in urinary incontinence.</td>
	</tr>	<tr>
		<td>25.</td>
		<td>Vitex agnus-castus fruit extract</td>
		<td>Experimental</td>
		<td>Not Available</td>
	</tr></table>
<div class="footer"> Copyright &copy : IIT Kanpur
</div>	
</div>
</body>
</html>